A Phase 2 interventional study of bevacizumab [Avastin] and docetaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 1 site in Austria. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-07-14.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.
Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 218th largest by enrollment of the 248 interventional ones that give a count, is one of 17 that started in 2006, is one of 157 in phase 2, and was the 210th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75 · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai JMT-Bio Inc. · Sites in China
Ages 18+
Jazz Pharmaceuticals · Sites in United States, Germany, Italy and 1 more country
Ages 18+
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
264 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 178 · Phase 3 55 · Phase 4 5
First in 1993; this study’s year is marked. 17 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 248 interventional studies. Of the 207 that completed or were terminated, 58 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 264 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 155th largest by enrollment of the 170 interventional ones that give a count, is one of 10 that started in 2006, is one of 65 in phase 2, and was the 123rd registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
3 of the studies testing docetaxel in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747338Phase 3Shanghai JMT-Bio Inc.A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer | 2026-12-16 |
| NCT05645380University of Kansas Medical CenterNeoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC | 2026-12 |
| NCT06409390H. Lee Moffitt Cancer Center and Research InstituteSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 264 studies testing docetaxel in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and Xeloda, given as pre-operative therapy to patients with primary breast cancer. Avastin will be administered every 3 weeks, for the first 5 cycles of chemotherapy. The anticipated time on study treatment is 3-12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab [Avastin] · Drug: docetaxel · Drug: capecitabine [Xeloda]
15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles
75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles
950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks
Percentage of Participants With Pathological Complete Response (pCR)
pCR was defined as the absence of signs for invasive tumor in the final surgical sample as judged by the local pathologist. Surgery was performed 2 to 4 weeks after the last chemotherapy cycle.
Time frame: Baseline, 20-24 weeks (final surgery, performed 2 to 4 weeks after the last chemotherapy cycle [Week 18])
Percentage of Participants With pCR, Clinical Complete Response (CR), or Clinical Partial Response (PR)
Percentage of participants with pCR plus the percentage of participants without pCR who achieved CR or PR as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\] 10 millimeters \[mm\]). No new lesions. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: Baseline, 20-24 weeks (final surgery, performed 2 to 4 weeks after the last chemotherapy cycle [Week 18])
Percentage of Participants Undergoing Breast-Conserving Surgery
Percentage of participants undergoing a breast-conserving procedure versus a modified radical mastectomy at final surgery, performed 2 to 4 weeks after the last chemotherapy cycle (Week 18)
Time frame: 20-24 weeks (final surgery, performed 2 to 4 weeks after the last chemotherapy cycle [Week 18])
| Milestone | Bevacizumab+Docetaxel+Capecitabine |
|---|---|
| Started | 18 |
| Completed | 18 |
| Not completed | 0 |
pCR was defined as the absence of signs for invasive tumor in the final surgical sample as judged by the local pathologist. Surgery was performed 2 to 4 weeks after the last chemotherapy cycle.
| percentage of participants | Bevacizumab+Docetaxel+Capecitabine |
|---|---|
| Percentage of Participants With Pathological Complete Response (pCR) | 22.22 (6.41 to 47.64) |
Percentage of participants with pCR plus the percentage of participants without pCR who achieved CR or PR as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\] 10 millimeters \[mm\]). No new lesions. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
| percentage of participants | Bevacizumab+Docetaxel+Capecitabine |
|---|---|
| Percentage of Participants With pCR, Clinical Complete Response (CR), or Clinical Partial Response (PR) | 72.22 (46.52 to 90.31) |
Percentage of participants undergoing a breast-conserving procedure versus a modified radical mastectomy at final surgery, performed 2 to 4 weeks after the last chemotherapy cycle (Week 18)
| percentage of participants | Bevacizumab+Docetaxel+Capecitabine |
|---|---|
| Percentage of Participants Undergoing Breast-Conserving Surgery | 83 (59 to 96) |
Collected over Baseline, every three weeks (Cycles 1 through 6), end-of-treatment, to 28 days after last dosage of study drug.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab+Docetaxel+Capecitabine | — | 5/18 (27.8%) | 18/18 (100%) |
| Event | Bevacizumab+Docetaxel+Capecitabine |
|---|---|
| Deep vein thrombosisVascular disorders | 2/18 |
| Intestinal perforationGastrointestinal disorders | 1/18 |
| General physical health deteriorationGeneral disorders | 1/18 |
| Impaired healingGeneral disorders | 1/18 |
| Neutropenic infectionInfections and infestations | 1/18 |
| Contralateral breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/18 |
| MenorrhagiaReproductive system and breast disorders | 1/18 |
| Event | Bevacizumab+Docetaxel+Capecitabine |
|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 17/18 |
| Nail disorderSkin and subcutaneous tissue disorders | 12/18 |
| ConstipationGastrointestinal disorders | 8/18 |
| LymphopeniaBlood and lymphatic system disorders | 8/18 |
| Blood lactate dehydrogenase increasedInvestigations | 8/18 |
| HyperglycaemiaMetabolism and nutrition disorders | 8/18 |
| FatigueGeneral disorders | 6/18 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 6/18 |
| StomatitisGastrointestinal disorders | 5/18 |
| AnaemiaBlood and lymphatic system disorders | 5/18 |
Intent-to-treat (ITT) population. All participants who received at least one dose of study drug.
| Age, Continuous(years) | Bevacizumab+Docetaxel+Capecitabine |
|---|---|
| Median | 48 (34 to 69) |
| Sex: Female, Male(Participants) | Bevacizumab+Docetaxel+Capecitabine |
|---|---|
| Female | 18 |
| Male | 0 |
The record gives a start of Feb 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 6 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Docetaxel